این سایت در حال حاضر پشتیبانی نمی شود و امکان دارد داده های نشریات بروز نباشند
International Journal of Hematology-Oncology and Stem Cell Research، جلد ۳، شماره ۲، صفحات ۱-۴
عنوان فارسی
چکیده فارسی مقاله
کلیدواژه‌های فارسی مقاله
عنوان انگلیسی First Complete Remission versus other- than- First Complete Remission in Acute Myelogenous Leukemia with Allogeneic Hematopoietic Stem Cell Transplantation
چکیده انگلیسی مقاله Introduction: The traditional goal of the treatment of Acute Myelogenous Leukemia is to produce and maintain a complete remission (CR).The difference in survival time was entirely attributable to the duration of time spent in CR .In this study, the outcome of AML patients with allogeneic HSCT in CR1 versus other than CR1 was compared. Patients and Methods: Since March 1991 until November 2008, from 420 AML patients, 312 patients in CR1 with a median age of 28 years and 108 patients in other- than- CR1 with a median age of 27 years, have undergone allogeneic HSCT. The male/female ratio was 168/144 in the CR1 group and 55/53 in other- than- CR1. In totals 391 patients received Peripheral Blood, 27 patients Bone Marrow and 2 patients, Cord Blood as sources of HSCT. Results: At present, 266 (85%) patients in CR1 and 73 (68%) patients in other- than-CR1 are living. The most common cause of death in CR1 group was Graft Versus Host Disease and in the other- than CR1 group was relapse. Median follow up time was 17 months (range: 1-158 months) . Six month Disease Free Survival (DFS) and Overall Survival (OS) in CR1 was 86% and 91% (SE=2%). 2-years DFS and OS in CR1 was 78% (SE=3%) and 85% (SE=2%). Six month DFS and OS in other- than- CR1 was 64% (SE=5%) and 75% (SE=4%). In this groups 2 years DFS and OS was 50% and 64% (SE=5%). It is to be noted that six month DFS and OS in transplanted patients with CR1 was significantly higher than in other- than- CR1 (p< 0.001). Furthermore, 2-years DFS and OS in patients with CR1 were better than the second group (P< 0.001). Conclusion: Although the results of HSCT in other than first complete remission is not as good as in first complete remission, it seems that it is good enough to advise doing allogeneic HSCT for these patients.
کلیدواژه‌های انگلیسی مقاله
نویسندگان مقاله اردشیر قوام زاده | ardeshir ghavamzadeh
hematology- oncology and stem cell transplantation research center, shariati hospital, tehran university of medical sciences, tehran, iran

سازمان اصلی تایید شده: دانشگاه علوم پزشکی تهران (Tehran university of medical sciences)

عاطفه مثنوی | atefeh masnavi
hematology- oncology and stem cell transplantation research center, shariati hospital, tehran university of medical sciences, tehran, iran

سازمان اصلی تایید شده: دانشگاه علوم پزشکی تهران (Tehran university of medical sciences)

فرناز خاتمی | farnaz khatami
hematology- oncology and stem cell transplantation research center, shariati hospital, tehran university of medical sciences, tehran, iran

سازمان اصلی تایید شده: دانشگاه علوم پزشکی تهران (Tehran university of medical sciences)

آرش جلالی | arash jalali
hematology- oncology and stem cell transplantation research center, shariati hospital, tehran university of medical sciences, tehran, iran

سازمان اصلی تایید شده: دانشگاه علوم پزشکی تهران (Tehran university of medical sciences)

محمد جهانی | mohammad jahani
hematology- oncology and stem cell transplantation research center, shariati hospital, tehran university of medical sciences, tehran, iran

سازمان اصلی تایید شده: دانشگاه علوم پزشکی تهران (Tehran university of medical sciences)

مسعود ایروانی | masoud iravani
hematology- oncology and stem cell transplantation research center, shariati hospital, tehran university of medical sciences, tehran, iran

سازمان اصلی تایید شده: دانشگاه علوم پزشکی تهران (Tehran university of medical sciences)

سید اسد o الله موسوی | seyed asad o allah mousavi
hematology- oncology and stem cell transplantation research center, shariati hospital, tehran university of medical sciences, tehran, iran

سازمان اصلی تایید شده: دانشگاه علوم پزشکی تهران (Tehran university of medical sciences)

بابک بهار | babak bahar
hematology- oncology and stem cell transplantation research center, shariati hospital, tehran university of medical sciences, tehran, iran

سازمان اصلی تایید شده: دانشگاه علوم پزشکی تهران (Tehran university of medical sciences)

نشانی اینترنتی http://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/207
فایل مقاله فایلی برای مقاله ذخیره نشده است
کد مقاله (doi)
زبان مقاله منتشر شده en
موضوعات مقاله منتشر شده
نوع مقاله منتشر شده Articles
برگشت به: صفحه اول پایگاه   |   نسخه مرتبط   |   نشریه مرتبط   |   فهرست نشریات